miR-1231通过靶向EGFR/PI3K/AKT通路抑制脑膜瘤细胞增殖研究

doi:10.3969/j.issn.1006-6233.2020.08.001

Abstract
Figure/Table
References
Related Citation (4)

Download: PDF (1993 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To investigate the effect of miR-1231 on meningioma cell proliferation by targeting the EGFR /PI3K /AKT pathway. Methods: Bioinformatics software and luciferase reporter gene experiments were used to analyze and verify the targeted binding between miR-1231 and EGFR. RT-PCR was used to detect miR-1231 expression and EGFR mRNA expression in meningiomas cells. Western blot was used to detect EGFR protein expression, PI3K and AKT phosphorylation levels; CCK-8 was used to detect meningioma cell viability; colony formation assay and EdU assay was used to detect meningioma cell proliferation. Results: Compared with normal meningeal cells, the expression of miR-1231 in meningiomas cells was significantly down-regulated (P<0.05), and the expression of EGFR was significantly up-regulated (P<0.05). EGFR was confirmed as a target gene of miR-1231. Compared with miR-NC group, miR-1231 significantly inhibited meningiomas cell proliferation and inhibited EGFR/PI3K/AKT pathway (P<0.05). Compared with anti-miR-NC group, anti- miR-1231 significantly promotes meningioma cell proliferation and activates the EGFR /PI3K /AKT pathway (P<0.05). Compared with miR-NC + EGFR-NC group, miR-1231 + EGFR-NC significantly inhibits meningiomas cells EGFR /PI3K /AKT pathway (P<0.05), significantly reduced cell proliferation (P<0.05). Compared with miR-NC + EGFR-NC group, miR-NC + EGFR significantly activated meningiomas cells PI3K /AKT pathway (P<0.05) ), significantly increased cell proliferation ability (P<0.05), and could significantly reverse the inhibitory effects of miR-1231 + EGFR-NC on PI3K /AKT pathway and cell proliferation ability of meningiomas cells. Conclusion: MiR-1231 can inhibit the proliferation of meningioma cells by targeting the EGFR to regulate the PI3K /AKT pathway.

Key words： miR-1231 Meningioma EGFR/PI3K/AKT pathway Cell proliferation

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2020.08.001 OR http://www.hbyxzzs.cn/EN/Y2020/V26/I8/1233

[1] Goldbrunner R, Minniti G, Preusser M, et al. EANO guidelines for the diagnosis and treatment of meningiomas[J]. The Lancet Oncology, 2016, 17(9): e383~e391.
[2] Rupaimoole R, Calin G A, Lopez-Berestein G, et al. miRNA deregulation in cancer cells and the tumor microenvironment[J]. Cancer discovery, 2016, 6(3): 235~246.
[3] Wang H, Wu J, Luo W J, et al. Low expression of miR-1231 in patients with glioma and its prognostic significance[J]. Nat Neurosci, 2018, 22: 8399~8405.
[4] Appert-Collin A, Hubert P, Crémel G, et al. Role of ErbB receptors in cancer cell migration and invasion[J]. Frontiers in pharmacology, 2015, 6: 283~293.
[5] Komori T. The 2016 WHO classification of tumours of the central nervous system: the major points of revision[J]. Neurologia medico-chirurgica, 2017, 57(7): 301~311.
[6] Lee J Y K, Pierce J T, Thawani J P, et al. Near-infrared fluorescent image-guided surgery for intracranial meningioma[J]. Journal of neurosurgery, 2017, 128(2): 380~390.
[7] Katar S, Baran O, Evran S, et al. Expression of miRNA-21, miRNA-107, miRNA-137 and miRNA-29b in meningioma[J]. Clinical neurology and neurosurgery, 2017, 156: 66~70.
[8] Chen S L, Ma M, Yan L, et al. Clinical significance of exosomal miR-1231 in pancreatic cancer[J]. Zhonghua zhong liu za zhi Chinese journal of oncology, 2019, 41(1): 46~49.
[9] Shang S, Wang J, Chen S, et al. Exosomal miRNA‐1231 derived from bone marrow mesenchymal stem cells inhibits the activity of pancreatic cancer[J]. Cancer medicine, 2019, 8(18): 7728~7740.
[10] Schuette W, Behringer D, Stoehlmacher J, et al. CHAMP: a phase II study of panitumumab with pemetrexed and cisplatin versus pemetrexed and cisplatin in the treatment of patients with advanced-stage primary nonsquamous non-small-cell lung cancer with particular regard to the KRAS status[J]. Clinical lung cancer, 2015, 16(6): 447~456.
[11] Pan H, Jiang T, Cheng N, et al. Long non-coding RNA BC087858 induces non-T790M mutation acquired resistance to EGFR-TKIs by activating PI3K/AKT and MEK/ERK pathways and EMT in non-small-cell lung cancer[J]. Oncotarget, 2016, 7(31): 49948~49960.
[12] Sun Z, Xue H, Wei Y, et al. Mucin O-glycosylating enzyme GALNT2 facilitates the malignant character of glioma by activating the EGFR/PI3K/Akt/mTOR axis[J]. Clinical Science, 2019, 133(10): 1167~1184.